A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Study ID
NCT02912949

Study type
Interventional

Study phase
Phase 2

Study status
Recruiting

Trial Acronym

Trial Summary

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)

More informations

Trial Starting Date

Jan 31,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

250